Scientists show how SARS-CoV-2 wreaks havoc in lungs
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have published the first detailed atomic-level model of the SARS-CoV-2 envelope protein in a study published June 8 in Nature Communications. The model shows how the virus interacts with lung proteins, helping to explain how SARS-CoV-2 causes extensive lung damage. Read More
Leveraging past flu pandemics helps build universal flu vaccine
Targeting regions of the influenza virus that do not often change may be an effective strategy for developing next-generation universal flu vaccines, according to new research published in Science Translational Medicine on June 2. Researchers interrogated immune responses from the 2009 H1N1 influenza pandemic to determine which targets to include in new vaccines. Read More
COVID-19 therapies could come from existing drugs
At least four drugs that have already been approved by the U.S. Food and Drug Administration may be effective as COVID-19 therapies, according to a study published on June 3 in Nature Communications by researchers from the Scripps Research Institute in La Jolla, CA. Read More
Royalties challenge risk and reward in AI drug development
As artificial intelligence (AI) becomes increasingly important for drug development, how should AI firms -- many of which are small startups -- structure their business relationships with pharmaceutical companies? Ulrik Kristensen of Emersion Insights offers a perspective. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
